Abdullah S. Alanazi , Hadiah Almutairi , Jeetendra Kumar Gupta , Dibyalochan Mohanty , Deepankar Rath , Ali A. AlOdan , Ahmed Mahal , Mahalaqua Nazli Khatib , Shilpa Gaidhane , Quazi Syed Zahiruddin , Sarvesh Rustagi , Prakasini Satapathy , Hashem Abu Serhan
{"title":"质子泵抑制剂治疗对骨质的影响:综述","authors":"Abdullah S. Alanazi , Hadiah Almutairi , Jeetendra Kumar Gupta , Dibyalochan Mohanty , Deepankar Rath , Ali A. AlOdan , Ahmed Mahal , Mahalaqua Nazli Khatib , Shilpa Gaidhane , Quazi Syed Zahiruddin , Sarvesh Rustagi , Prakasini Satapathy , Hashem Abu Serhan","doi":"10.1016/j.bonr.2024.101741","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs) are among the most commonly prescribed medications worldwide for acid-related disorders. While their short-term efficacy and safety are well-established, concerns regarding their long-term effects on bone health have emerged. This umbrella review aimed to synthesize the available findings on the associations between PPI use and bone metabolism outcomes.</p></div><div><h3>Methods</h3><p>An electronic search was conducted using PubMed, Web of Science, Embase, and the Cochrane Database up to September 16, 2023. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies that evaluated the relationship between PPIs and bone metabolism outcomes were included. Data extraction, quality appraisal, and synthesis were performed in line with the Joanna Briggs Institute and PRISMA guidelines. The strength of the evidence was graded using the GRADE criteria. Statistical analysis was performed in R version 4.3.</p></div><div><h3>Results</h3><p>Out of 299 records, 27 studies met the inclusion criteria. The evidence indicated a statistically significant increased risk of fractures, notably hip, spine, and wrist fractures, in PPI users. PPI use was associated with changes in Bone Mineral Density (BMD) across various bones, though the clinical relevance of these changes remains uncertain. Furthermore, PPI-induced hypomagnesemia, which can influence bone health, was identified. A notable finding was the increased risk of dental implant failures in PPI users. However, the certainty of most of the evidence ranged from very low to low based on GRADE criteria.</p></div><div><h3>Conclusion</h3><p>The long-term use of PPIs may be associated with adverse bone health outcomes, including increased fracture risk, alterations in BMD, hypomagnesemia, and dental implant failure. While these findings highlight potential concerns for long-term PPI users, the current evidence's low certainty underscores the need for robust, high-quality research to clarify these associations.</p></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"20 ","pages":"Article 101741"},"PeriodicalIF":2.1000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352187224000081/pdfft?md5=f55bed093e5f5e0a38c45b5cc01a18f6&pid=1-s2.0-S2352187224000081-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Osseous implications of proton pump inhibitor therapy: An umbrella review\",\"authors\":\"Abdullah S. Alanazi , Hadiah Almutairi , Jeetendra Kumar Gupta , Dibyalochan Mohanty , Deepankar Rath , Ali A. AlOdan , Ahmed Mahal , Mahalaqua Nazli Khatib , Shilpa Gaidhane , Quazi Syed Zahiruddin , Sarvesh Rustagi , Prakasini Satapathy , Hashem Abu Serhan\",\"doi\":\"10.1016/j.bonr.2024.101741\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs) are among the most commonly prescribed medications worldwide for acid-related disorders. While their short-term efficacy and safety are well-established, concerns regarding their long-term effects on bone health have emerged. This umbrella review aimed to synthesize the available findings on the associations between PPI use and bone metabolism outcomes.</p></div><div><h3>Methods</h3><p>An electronic search was conducted using PubMed, Web of Science, Embase, and the Cochrane Database up to September 16, 2023. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies that evaluated the relationship between PPIs and bone metabolism outcomes were included. Data extraction, quality appraisal, and synthesis were performed in line with the Joanna Briggs Institute and PRISMA guidelines. The strength of the evidence was graded using the GRADE criteria. Statistical analysis was performed in R version 4.3.</p></div><div><h3>Results</h3><p>Out of 299 records, 27 studies met the inclusion criteria. The evidence indicated a statistically significant increased risk of fractures, notably hip, spine, and wrist fractures, in PPI users. PPI use was associated with changes in Bone Mineral Density (BMD) across various bones, though the clinical relevance of these changes remains uncertain. Furthermore, PPI-induced hypomagnesemia, which can influence bone health, was identified. A notable finding was the increased risk of dental implant failures in PPI users. However, the certainty of most of the evidence ranged from very low to low based on GRADE criteria.</p></div><div><h3>Conclusion</h3><p>The long-term use of PPIs may be associated with adverse bone health outcomes, including increased fracture risk, alterations in BMD, hypomagnesemia, and dental implant failure. While these findings highlight potential concerns for long-term PPI users, the current evidence's low certainty underscores the need for robust, high-quality research to clarify these associations.</p></div>\",\"PeriodicalId\":9043,\"journal\":{\"name\":\"Bone Reports\",\"volume\":\"20 \",\"pages\":\"Article 101741\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2352187224000081/pdfft?md5=f55bed093e5f5e0a38c45b5cc01a18f6&pid=1-s2.0-S2352187224000081-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bone Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352187224000081\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352187224000081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景质子泵抑制剂(PPIs)是全球治疗酸相关疾病最常用的处方药之一。虽然其短期疗效和安全性已得到公认,但人们开始关注其对骨骼健康的长期影响。本综述旨在综合PPI使用与骨代谢结果之间关系的现有研究结果。方法使用PubMed、Web of Science、Embase和Cochrane数据库进行电子检索,检索时间截至2023年9月16日。纳入了评估 PPI 与骨代谢结果之间关系的随机对照试验 (RCT) 和观察性研究的系统综述和荟萃分析。按照乔安娜-布里格斯研究所(Joanna Briggs Institute)和PRISMA指南进行了数据提取、质量评估和综合。证据的强度采用 GRADE 标准进行分级。结果在 299 条记录中,有 27 项研究符合纳入标准。证据表明,PPI 使用者发生骨折(尤其是髋部、脊柱和腕部骨折)的风险在统计学上有显著增加。使用 PPI 与各种骨骼的骨矿密度 (BMD) 变化有关,但这些变化的临床意义仍不确定。此外,还发现了 PPI 引起的低镁血症,这可能会影响骨骼健康。一个值得注意的发现是,PPI 使用者种植牙失败的风险增加。结论长期使用 PPIs 可能与不良骨健康结果有关,包括骨折风险增加、BMD 改变、低镁血症和牙科植入失败。虽然这些发现凸显了长期服用 PPI 的潜在问题,但目前证据的确定性较低,这突出表明需要进行强有力的、高质量的研究来澄清这些关联。
Osseous implications of proton pump inhibitor therapy: An umbrella review
Background
Proton pump inhibitors (PPIs) are among the most commonly prescribed medications worldwide for acid-related disorders. While their short-term efficacy and safety are well-established, concerns regarding their long-term effects on bone health have emerged. This umbrella review aimed to synthesize the available findings on the associations between PPI use and bone metabolism outcomes.
Methods
An electronic search was conducted using PubMed, Web of Science, Embase, and the Cochrane Database up to September 16, 2023. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies that evaluated the relationship between PPIs and bone metabolism outcomes were included. Data extraction, quality appraisal, and synthesis were performed in line with the Joanna Briggs Institute and PRISMA guidelines. The strength of the evidence was graded using the GRADE criteria. Statistical analysis was performed in R version 4.3.
Results
Out of 299 records, 27 studies met the inclusion criteria. The evidence indicated a statistically significant increased risk of fractures, notably hip, spine, and wrist fractures, in PPI users. PPI use was associated with changes in Bone Mineral Density (BMD) across various bones, though the clinical relevance of these changes remains uncertain. Furthermore, PPI-induced hypomagnesemia, which can influence bone health, was identified. A notable finding was the increased risk of dental implant failures in PPI users. However, the certainty of most of the evidence ranged from very low to low based on GRADE criteria.
Conclusion
The long-term use of PPIs may be associated with adverse bone health outcomes, including increased fracture risk, alterations in BMD, hypomagnesemia, and dental implant failure. While these findings highlight potential concerns for long-term PPI users, the current evidence's low certainty underscores the need for robust, high-quality research to clarify these associations.
Bone ReportsMedicine-Orthopedics and Sports Medicine
CiteScore
4.30
自引率
4.00%
发文量
444
审稿时长
57 days
期刊介绍:
Bone Reports is an interdisciplinary forum for the rapid publication of Original Research Articles and Case Reports across basic, translational and clinical aspects of bone and mineral metabolism. The journal publishes papers that are scientifically sound, with the peer review process focused principally on verifying sound methodologies, and correct data analysis and interpretation. We welcome studies either replicating or failing to replicate a previous study, and null findings. We fulfil a critical and current need to enhance research by publishing reproducibility studies and null findings.